BMS

View All

etrasimod-for-ulcerative-colitis-treatment
New Player in Ulcerative Colitis Treatment: Pfizer’s Etrasimod Entry Counters BMS’ Zeposia

Bristol Myers Squibb’s Zeposia has lost its exclusive status as the sole S1P receptor modulator available for ulcerative colitis treatment. The FDA has granted approval for Pfizer’s ulcerative colitis medication, Etrasimod, under the brand name Velsipity. This decision comes after the publication of Phase III resul...

Find More

Rare diseases challenges | Rare diseases clinical trials, incidence, and funding
The Paradox of Rare: Chalking out Challenges in the Rare Disease Market

How is a Rare disease defined? Well, it depends on the geography in question, since there is no universal definition, even so, the definition revolves around the point of prevalence or incidence of rare disease. If we talk about the United States, a rare disease affects fewer than 200,000 people (Orphan Drug Act). ...

Find More

Personalized Medicine
Bristol-Myers Squibb to nix; Pfizer commits $100M; Merck and GSK production issues; Shire unloads plant

Loom of Patent Expiry leads Bristol-Myers Squibb to nix 58 marketing jobs Bristol-Myers Squibb will soon bid farewell to its exclusive lock on a pair of HIV drugs—and, as a result, 58 workers will bid farewell to their jobs. The company is making changes to their HIV portfolio businessin anticipation of end-of-year ...

Find More

Roche, Boehringer tout; Pfizer, Bristol-Myers got sued; FDA commissioner unveils; EpicGenetics expands

Roche, Boehringer tout new idiopathic pulmonary fibrosis analyses to boost their rival medications The idiopathic pulmonary fibrosis (IPF) market-share battle between Roche’s Esbriet and Boehringer Ingelheim’s Ofev hasn’t let up since the FDA green-lighted the medications in October 2014. And this week, both drugmak...

Find More

Lilly moves ahead; Authorities raid; Bristol-Myers, AZ in legal; PhRMA expected to weed out

Lilly moves forward with biologics plant expansion in Ireland Eli Lilly has confirmed that it will move forward with plans to add a manufacturing line at its site in Kindsdale, County Cork in Ireland. The construction might begin in coming months and commissioning will begin in 2019. The expansion is expected to add...

Find More

Therapeutics
Merck’s Keytruda sales; Valeant on name change; Pfizer – BMS; Amgen puts Repatha outcomes for deal

Merck beats Q1 estimates as Keytruda sales double Merck is the victim of its own success, judging from its first-quarter report. The company beat sales and earnings estimates, and it upped its guidance for the year, despite some significant suffering from generic competition. Sales of its hit immuno-oncology drug Ke...

Find More

Diminishing pipeline of Galectin Inhibitors

Galectin belongs to the family of lectins that has the ability to bind to β-galactose, and binds to glycoproteins that are present on the extracellular as well as intracellular surface. Galectins have varied roles in many cellular functions like adhesion, migration, polarity, chemotaxis, proliferation, apoptosis and...

Find More